|
Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.
|
 |
|
AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.
|
|
|
Under the agreement, Insilico Medicine will receive R&D funding for each programme.
|
|
|
THX Pharma is set to receive total payments up to $206.1m.
|
|
|
REGENXBIO plans to request a Type A meeting with the FDA to discuss the CRL and its planned BLA resubmission.
|
|
|
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
|
|
